Straits Times Index
3,199.78 +0.77 (+0.02%) Nikkei
29,284.87 +69.35 (+0.24%) Hang Seng
26,127.59 +340.38 (+1.32%) FTSE 100
7,217.53 +13.70 (+0.19%) BTC-USD
63,946.56 +1,341.80 (+2.14%) CMC Crypto 200
1,480.44 +17.08 (+1.17%)
MannKind Corporation (MNKD)
| Previous close | 4.1600 |
| Open | 4.3020 |
| Bid | 4.0900 x 1800 |
| Ask | 4.1000 x 47300 |
| Day's range | 4.0700 - 4.3020 |
| 52-week range | 1.9400 - 6.2500 |
| Volume | 4,804,349 |
| Avg. volume | 2,865,730 |
| Market cap | 1.036B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3590 |
| Earnings date | 02 Nov 2021 - 08 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.17 |
- Zacks
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
- Motley Fool
Why Shares of MannKind Corporation Are Falling This Morning
Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.
- Investing.com
United Therapeutics, Mannkind Fall After FDA Declines to Approve Lung Drug
By Sam Boughedda
